PL2877201T3 - Ciekła formulacja długo działającej insuliny i peptydu insulinotropowego - Google Patents
Ciekła formulacja długo działającej insuliny i peptydu insulinotropowegoInfo
- Publication number
- PL2877201T3 PL2877201T3 PL13822545T PL13822545T PL2877201T3 PL 2877201 T3 PL2877201 T3 PL 2877201T3 PL 13822545 T PL13822545 T PL 13822545T PL 13822545 T PL13822545 T PL 13822545T PL 2877201 T3 PL2877201 T3 PL 2877201T3
- Authority
- PL
- Poland
- Prior art keywords
- long
- liquid formulation
- acting insulin
- insulinotropic peptide
- insulinotropic
- Prior art date
Links
- 102000016261 Long-Acting Insulin Human genes 0.000 title 1
- 108010092217 Long-Acting Insulin Proteins 0.000 title 1
- 229940100066 Long-acting insulin Drugs 0.000 title 1
- 230000002473 insulinotropic effect Effects 0.000 title 1
- 239000012669 liquid formulation Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120081478 | 2012-07-25 | ||
| EP13822545.3A EP2877201B1 (en) | 2012-07-25 | 2013-07-25 | A liquid formulation of long-acting insulin and insulinotropic peptide |
| PCT/KR2013/006676 WO2014017849A1 (en) | 2012-07-25 | 2013-07-25 | A liquid formulation of long-acting insulin and insulinotropic peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2877201T3 true PL2877201T3 (pl) | 2019-12-31 |
Family
ID=49997583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13822545T PL2877201T3 (pl) | 2012-07-25 | 2013-07-25 | Ciekła formulacja długo działającej insuliny i peptydu insulinotropowego |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9833516B2 (pl) |
| EP (1) | EP2877201B1 (pl) |
| JP (2) | JP6403670B2 (pl) |
| KR (1) | KR102088863B1 (pl) |
| CN (2) | CN110269930A (pl) |
| AR (1) | AR092862A1 (pl) |
| AU (1) | AU2013293720B2 (pl) |
| BR (1) | BR112015001593B1 (pl) |
| CA (1) | CA2880037C (pl) |
| CY (1) | CY1122146T1 (pl) |
| DK (1) | DK2877201T3 (pl) |
| ES (1) | ES2743918T3 (pl) |
| HK (1) | HK1204291A1 (pl) |
| HU (1) | HUE045837T2 (pl) |
| MX (1) | MX358647B (pl) |
| PL (1) | PL2877201T3 (pl) |
| PT (1) | PT2877201T (pl) |
| RU (1) | RU2643766C2 (pl) |
| TW (1) | TWI630214B (pl) |
| WO (1) | WO2014017849A1 (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068164T2 (hu) | 2008-10-17 | 2024-12-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| EP3091995B1 (en) * | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| MX369656B (es) | 2014-01-20 | 2019-11-15 | Hanmi Pharm Ind Co Ltd | Insulina de accion prolongada y uso de la misma. |
| DK3127923T3 (da) * | 2014-03-31 | 2021-11-22 | Hanmi Pharm Ind Co Ltd | Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) * | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| AU2017332408B2 (en) | 2016-09-23 | 2022-02-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| AU2018239037B2 (en) | 2017-03-23 | 2022-05-26 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| CN111406073A (zh) * | 2017-09-29 | 2020-07-10 | 韩美药品株式会社 | 具有提高功效的持久性蛋白质缀合物 |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CN110628723B (zh) * | 2019-09-05 | 2021-05-04 | 清华大学 | 基因修饰MSCs治疗2型糖尿病 |
| JP2023505493A (ja) * | 2019-12-06 | 2023-02-09 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Ｆｃ多量体の安定組成物 |
| US20230285584A1 (en) * | 2020-05-22 | 2023-09-14 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glp-2 |
| US20230210949A1 (en) * | 2020-05-22 | 2023-07-06 | Hanmi Pharm Co., Ltd. | Liquid formulation |
| WO2021235916A1 (ko) * | 2020-05-22 | 2021-11-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제 |
| IL298396A (en) * | 2020-05-22 | 2023-01-01 | Hanmi Pharm Ind Co Ltd | Liquid formulation of long-acting conjugate of glucagon derivative |
| WO2025089468A1 (ko) * | 2023-10-27 | 2025-05-01 | 주식회사 엔솔바이오사이언스 | 펩타이드 함유 액상제제 및 그 제조방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DK1355942T3 (da) * | 2000-12-07 | 2008-11-17 | Lilly Co Eli | GLP-1-fusionsproteiner |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| EP1684793B1 (en) * | 2003-11-13 | 2011-09-21 | Novo Nordisk A/S | Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant |
| JP5248113B2 (ja) * | 2004-11-12 | 2013-07-31 | ノヴォ ノルディスク アー／エス | ペプチドの安定な処方 |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| UA96473C2 (ru) * | 2007-03-22 | 2011-11-10 | Имклоун Ллк | Жидкая стойкая композиция, которая содержит антитело imc-а12 |
| EA201070121A1 (ru) * | 2007-07-10 | 2010-06-30 | Эли Лилли Энд Компани | Лекарственная форма, содержащая слитый белок glp-1-fc |
| JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| US8481485B2 (en) * | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| SG10201500871TA (en) * | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| JP5657698B2 (ja) * | 2010-01-19 | 2015-01-21 | ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． | 持続型顆粒球コロニー刺激因子結合体の液剤 |
| BR112012017982A2 (pt) * | 2010-01-19 | 2016-05-03 | Hanmi Science Co Ltd | formulações líquidas para conjugado de eritropoietina de longa ação |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| KR101324828B1 (ko) | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
| KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
| KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
| KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії |
-
2013
- 2013-07-24 AR ARP130102652A patent/AR092862A1/es not_active Application Discontinuation
- 2013-07-25 EP EP13822545.3A patent/EP2877201B1/en active Active
- 2013-07-25 CA CA2880037A patent/CA2880037C/en active Active
- 2013-07-25 CN CN201910644022.4A patent/CN110269930A/zh active Pending
- 2013-07-25 MX MX2015001217A patent/MX358647B/es active IP Right Grant
- 2013-07-25 KR KR1020130087917A patent/KR102088863B1/ko active Active
- 2013-07-25 PL PL13822545T patent/PL2877201T3/pl unknown
- 2013-07-25 ES ES13822545T patent/ES2743918T3/es active Active
- 2013-07-25 HU HUE13822545A patent/HUE045837T2/hu unknown
- 2013-07-25 PT PT13822545T patent/PT2877201T/pt unknown
- 2013-07-25 TW TW102126622A patent/TWI630214B/zh active
- 2013-07-25 US US14/416,231 patent/US9833516B2/en active Active
- 2013-07-25 DK DK13822545.3T patent/DK2877201T3/da active
- 2013-07-25 AU AU2013293720A patent/AU2013293720B2/en active Active
- 2013-07-25 HK HK15104957.6A patent/HK1204291A1/xx unknown
- 2013-07-25 BR BR112015001593-0A patent/BR112015001593B1/pt active IP Right Grant
- 2013-07-25 CN CN201380039763.0A patent/CN104519904A/zh active Pending
- 2013-07-25 WO PCT/KR2013/006676 patent/WO2014017849A1/en not_active Ceased
- 2013-07-25 RU RU2015104489A patent/RU2643766C2/ru active
- 2013-07-25 JP JP2015524185A patent/JP6403670B2/ja active Active
-
2018
- 2018-05-31 JP JP2018104433A patent/JP6686070B2/ja active Active
-
2019
- 2019-08-22 CY CY20191100898T patent/CY1122146T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140015208A (ko) | 2014-02-06 |
| CN104519904A (zh) | 2015-04-15 |
| ES2743918T3 (es) | 2020-02-21 |
| JP2018138615A (ja) | 2018-09-06 |
| CA2880037A1 (en) | 2014-01-30 |
| US9833516B2 (en) | 2017-12-05 |
| PT2877201T (pt) | 2019-09-10 |
| AU2013293720B2 (en) | 2018-05-10 |
| HUE045837T2 (hu) | 2020-01-28 |
| JP6686070B2 (ja) | 2020-04-22 |
| US20150190528A1 (en) | 2015-07-09 |
| KR102088863B1 (ko) | 2020-03-13 |
| MX2015001217A (es) | 2015-09-07 |
| BR112015001593B1 (pt) | 2023-12-26 |
| BR112015001593A2 (pt) | 2019-07-30 |
| JP2015524429A (ja) | 2015-08-24 |
| CA2880037C (en) | 2021-08-17 |
| CY1122146T1 (el) | 2021-01-27 |
| CN110269930A (zh) | 2019-09-24 |
| HK1204291A1 (en) | 2015-11-13 |
| MX358647B (es) | 2018-08-29 |
| TWI630214B (zh) | 2018-07-21 |
| RU2015104489A (ru) | 2016-09-20 |
| EP2877201B1 (en) | 2019-06-05 |
| EP2877201A4 (en) | 2016-03-30 |
| DK2877201T3 (da) | 2019-09-16 |
| AR092862A1 (es) | 2015-05-06 |
| EP2877201A1 (en) | 2015-06-03 |
| AU2013293720A1 (en) | 2015-02-12 |
| JP6403670B2 (ja) | 2018-10-10 |
| RU2643766C2 (ru) | 2018-02-05 |
| TW201410704A (zh) | 2014-03-16 |
| WO2014017849A1 (en) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE045837T2 (hu) | Hosszantartó hatású inzulin és inzulinotróp peptid folyékony készítményei | |
| HUE042246T2 (hu) | Folyékony nyújtott hatású inzulin konjugátum készítmény | |
| PL2877158T3 (pl) | Ciekła formulacja długo działającego koniugatu peptydu insulinotropowego | |
| PL2866825T3 (pl) | <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div> | |
| PL2575865T3 (pl) | Kompozycja farmaceutyczna obejmująca AVE0010 i insulinę glargine | |
| EP2756378A4 (en) | USER INTERFACE ROLL BASE FOR LIMITED DISPLAY DEVICES | |
| ZA201409269B (en) | Liquid formulation | |
| EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| IL238651A0 (en) | Long-acting, single-chain insulin analogs | |
| IL245109A0 (en) | A stable formulation of insulin glulisine | |
| IL230309B (en) | A drug release device and a cartridge that connects to it | |
| IL242831B (en) | A preparation with a constant ratio of insulin glargine/lixisentide | |
| EP2724740A4 (en) | SYRINGE | |
| ZA201208605B (en) | Stable ready to use injectable paracetamol formulation | |
| IL235830A0 (en) | New dosage and formulation | |
| EP2586324A4 (en) | TRANSDERMAL ADMINISTRATION BRACELET | |
| EP2683429A4 (en) | RETRACTABLE SYRINGE HAVING LOCKABLE PISTON | |
| ZA201405249B (en) | Transdermal hormone delivery | |
| EP2826507A4 (en) | PRE-FILLED SYRINGE WITH MIXTURE BEFORE USE | |
| GB201311029D0 (en) | Pre-filled sing-use syringe | |
| GB201209786D0 (en) | A pre-filled drug container and method for manufacturing a drug container suitable for use as a pre-filled drug container | |
| GB201112578D0 (en) | Pharmaceutical preparation and use | |
| GB201213522D0 (en) | Single use syringe |